Previous 10 | Next 10 |
Aeglea BioTherapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass. , Oct. 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential...
Aeglea BioTherapeutics to Participate in Upcoming September Conference PR Newswire WALTHAM, Mass. , Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics w...
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) is one of today's top gainers. The company's shares are currently up -1.98% on the day to $14.72. Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and f...
Aeglea BioTherapeutics Announces Reverse Stock Split PR Newswire WALTHAM, Mass. , Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to tra...
2023-09-05 11:24:21 ET More on Aeglea BioTherapeutics Seeking Alpha’s Quant Rating on Aeglea BioTherapeutics Historical earnings data for Aeglea BioTherapeutics Financial information for Aeglea BioTherapeutics Aeglea initiated with Buy at Stifel citing...
2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...
2023-08-11 10:25:25 ET Aeglea BioTherapeutics press release ( NASDAQ: AGLE ): Q2 GAAP EPS of -$2.27. $236.7 million of cash and cash equivalents and restricted cash as of June 30, 2023 For further details see: Aeglea BioTherapeutics GAAP EPS of -$2.27
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results PR Newswire Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) port...
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma PR Newswire Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone ...
2023-07-25 15:23:05 ET Aeglea BioTherapeutics ( NASDAQ: AGLE ) traded higher on Tuesday after Stifel launched its coverage with a Buy recommendation citing its potential against inflammatory bowel disorders, ulcerative colitis, and Crohn's disease. Despite rising competition amo...
News, Short Squeeze, Breakout and More Instantly...
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire Company will begin trading on Nasdaq under trading sy...
2023-11-20 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β...